CLINICAL TRIALS
Advancing 8R‑70CAR T-Cell Therapy Through Clinical Trials
Our clinical-stage 8R‑70CAR incorporates a GPS-enabled CAR design engineered to enahce CAR T-cell trafficking to tumors. The program is being evaluated across adult and pediatric brain tumors, establishing a foundation for potential development in additional solid and liquid tumors
Explore the Studies → Why Better Treatments Are Urgently Needed
Clinical Programs
The 8R‑70CAR T-cell platform is advancing through three Phase I clinical programs spanning adult glioblastoma, pediatric high-grade glioma and diffuse intrinsic pontine glioma (DIPG), and brain metastases. The FDA has granted Orphan Drug Designation (ODD, DRU-2025-11271) to 8R-70CAR T-cell therapy for the treatment of malignant glioma.
IMPACT: IL-8-Receptor-Modified CD70 Patient-derived Activated CAR T cell Therapy
IMPACT
Adult Glioblastoma
Phase I • NCT05353530
A Phase I study evaluating the safety, feasibility, cellular kinetics, and preliminary activity of intravenously administered 8R‑70CAR T cells in adults with newly diagnosed glioblastoma.
View Study →pIMPACT
Pediatric High-Grade Glioma, including DIPG
Phase I • NCT06946680
A Phase I study evaluating the safety, feasibility, cellular kinetics, and preliminary activity of 8R‑70CAR T cells in children and adolescents with high-grade glioma, including DIPG.
View Study →IMPACT-MET
Brain Metastases
Phase I • NCT07569263
A Phase I study evaluating the safety, feasibility, cellular kinetics, and preliminary activity of intravenously administered 8R‑70CAR T cells in adults with brain metastases.
View Study →8R-70CAR T-Cell Treatment Journey
